Natera, Inc.
NTRA
Rank in Stocks
#410
Natera, Inc. is a diagnostics company focused on developing and commercializing... Natera, Inc. is a diagnostics company focused on developing and commercializing a wide array of molecular testing services globally. Its portfolio includes several key offerings: Panorama, a non-invasive prenatal test (NIPT) that screens for chromosomal abnormalities in a fetus using a blood sample from the mother, and also determines zygosity in twin pregnancies. Vistara, designed to identify single-gene disorders by screening for specific single-gene mutations. Horizon, a comprehensive carrier screening test to determine an individual's carrier status for various genetic diseases. Spectrum, utilized during in vitro fertilization (IVF) cycles to detect chromosomal anomalies or inherited genetic conditions. Anora, a miscarriage analysis product that examines fetal chromosomes to help understand the cause of pregnancy loss. Non-invasive paternity testing, which establishes paternity during gestation using blood samples from both the pregnant mother and the alleged father. Beyond reproductive health, Natera also provides specialized tests: Signatera, a sophisticated circulating tumor DNA (ctDNA) technology capable of screening for a generic set of mutations, independent of the individual's specific tumor characteristics. Prospera, a test used to assess and monitor organ transplant rejection. Additionally, the company offers Constellation, a cloud-based software platform that provides laboratory clients with access to Natera's proprietary algorithms and bioinformatics, enabling them to validate and launch their own tests. Natera distributes its products through a direct sales team and an extensive network of approximately 100 laboratory and distribution partners. The company has strategic partnerships, including one with BGI Genomics Co., Ltd. for the development, manufacturing, and commercialization of NGS-based genetic testing assays, and another with Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. Founded in 2003, Natera, Inc. is headquartered in Austin, Texas. It was formerly known as Gene Security Network, Inc. before changing its name in 2012.
Share Price
$408.43
Market Cap
$58.87B
Change (1 day)
2.26%
Change (1 year)
116.56%
Country
US
Trade Natera, Inc. (NTRA)
Category
Healthcare
P/E ratio for Natera, Inc. (NTRA)
P/E ratio as of October 2026 TTM: -290.26
According to Natera, Inc. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -290.26. At the end of 2023 the company had a P/E ratio of -16.57.
P/E ratio history for Natera, Inc. from 2012 to 2026
P/E ratio at the end of each year
| Year | P/E Ratio | Change |
|---|---|---|
| 2026 (TTM) | -290.26 | 179.96% |
| 2024 | -103.68 | 525.80% |
| 2023 | -16.57 | 129.58% |
| 2022 | -7.22 | -59.75% |
| 2021 | -17.93 | -48.91% |
| 2020 | -35.09 | 86.94% |
| 2019 | -18.77 | 198.53% |
| 2018 | -6.29 | 78.85% |
| 2017 | -3.52 | -44.11% |
| 2016 | -6.29 | -14.08% |
| 2015 | -7.32 | -94.29% |
| 2014 | -128.17 | 620.30% |
| 2013 | -17.79 | 2,308.87% |
| 2012 | -0.74 | 0.00% |
P/E ratio for similar companies or competitors
| Company | P/E Ratio | P/E Ratio Difference | Country |
|---|---|---|---|
| 36.15 | -112.46% |
US
|
|
| 39.77 | -113.70% |
US
|
|
| - | - |
CN
|
|
| 34.18 | -111.78% |
US
|
|
| 32.24 | -111.11% |
US
|
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.